Skip to content
Sign in
SWC 2026 FinalistGrand Final: Main Stage

StemSight

Tampere spin-off building scalable iPSC-derived corneal cell therapy for limbal stem cell deficiency, targeting first clinical trials around 2027.

Tampere, Finland, EuropeBiotech & life sciences, Ophthalmic cell therapy (cornea)Finland (presumed)
Stage
SeedNo documented AI
Product
R&DNone known
Funding raised
$3Mdisclosed
Founded
20215 years ago
Founders
4Laura, Tanja…
Global score
3.3Grade DRank 123 of 151

Overview

StemSight develops stem cell-based therapies to restore vision, targeting limbal stem cell deficiency of the cornea.

Traction

None known

Corneal cell therapy at preclinical stage, clinical trials targeted around 2027; patent granted in Singapore (June 2026) for its scalable stem cell technology.

Market

Limbal stem cell deficiency therapies (cornea)

Limbal stem cell deficiency causes blindness and current treatments depend on scarce donor tissue or the patient's own healthy eye. An off-the-shelf, iPSC-derived product could treat more patients at scale. Value will be captured through regulatory approval and ophthalmology centres or through licensing to larger cell-therapy players. It is a rare-disease market with long clinical timelines.

Addressable market

2025
$0.2B
2030
$0.3B
+8.84% a year

Limbal stem cell deficiency therapies: ~$0.21bn (2024) to $0.53bn in 2035, +8.84%/year (Spherical Insights); DelveInsight uses a broader $2.7bn.

Customers

Corneal surgeons and specialised ophthalmology centres; pharma/cell-therapy licensees

Who signs the cheque

Hospital ophthalmology departments and payers (later); pharma BD teams (licensing)

Geographies

  • Finland
  • Europe
  • Singapore (patent)

Drivers

  • Unmet need and donor tissue scarcity
  • Maturing iPSC manufacturing
  • Regulatory incentives for rare/orphan therapies

Headwinds

  • Preclinical stage
  • High regulatory and manufacturing costs
  • Small market

The limbal stem cell deficiency market is estimated at ~$0.21bn (2024) and $0.53bn in 2035 (+8.8%/year) according to Spherical Insights; DelveInsight uses a much broader scope ($2.7bn).

Scalability 4/10. Cell therapy with complex manufacturing and strict regulation; rare disease market.

Market source: sphericalinsights.com

Technology

Category

Cell therapy (iPSC-derived)

No documented AI

Maturity

  1. R&D
  2. Prototype
  3. Pilot
  4. On the market
  5. Scaling

R&D

How it works

Corneal cells are derived from induced pluripotent stem cells using a scalable process. A patent was granted in Singapore in June 2026 for the scalable stem cell technology.

Moat

Strong scientific and IP base (Tampere University research, granted patent); manufacturing know-how will be key.

Differentiation

Allogeneic, scalable source instead of donor or autologous limbal tissue.

Integration points

  • GMP media and reagent suppliers
  • Ophthalmic diagnostics for patient selection and endpoints
  • Ophthalmic biomaterials/carriers
  • Cell-therapy CDMOs

Depends on

  • GMP manufacturing and xeno-free reagents
  • Regulatory approval (ATMP)
  • Clinical trial funding

Use of AI

No use of AI mentioned

Product in detail

Corneal cells derived from induced pluripotent stem cells (iPS); clinical trials targeted around 2027.

Business

Model
Develop to clinical proof of concept, then license or partner; potential direct supply to centres.
Revenue logic
Licensing milestones/royalties or per-treatment pricing (future).
Go-to-market
Partnering with pharma/cell-therapy players after first-in-human data.

Next milestones

  1. Clinical trial authorisation
  2. GMP process lock
  3. Series A or non-dilutive EU funding

Key risks

  • Clinical and regulatory risk
  • Manufacturing cost
  • Funding gap to the clinic

Opportunities

4 found in the network

Concrete moves for StemSight inside the network: who to sell to, sell through, build with or raise from, each with the reasoning, the evidence and the first step.

  • Customers 1
  • Co-development 2
  • Investors 1

Customers1

Who could buy, or sell through

Qualify defined, serum-free media for StemSight's manufacturing process

Moving iPSC-derived cells to the clinic requires defined, low-variability media; Defined Bioscience sells exactly this for pluripotent stem cells. A supply and co-development agreement lowers StemSight's cost of goods and gives Defined Bioscience a clinical-pathway customer.

40%confidence

Evidence from the records

  • “Fully defined media formulations with stabilized growth factors, reducing the cost and variability of stem cell culture.”
  • “Corneal cells derived from induced pluripotent stem cells (iPS); clinical trials targeted around 2027.”
  • “patent granted in Singapore (June 2026) for its scalable stem cell technology.”
If it works
Lower manufacturing cost and a qualified supplier for the clinical process.
First step
Request HiDef-B8 samples and run a comparison against current media.

Co-development2

An integration or joint product

Use portable corneal topography for patient selection and trial endpoints

Corneal cell-therapy trials need objective corneal-surface measurements; Ocuwell's handheld device delivers topography comparable to reference machines. Using it in StemSight trials helps standardise endpoints and gives Ocuwell clinical-trial use.

25%confidence

Evidence from the records

  • “OCUTOP: handheld device providing corneal topography data equivalent to reference machines, with cloud solutions.”
  • “Corneal cell therapy at preclinical stage, clinical trials targeted around 2027”
If it works
A trial-endpoint partnership and joint publications.
First step
Organise a call between the two clinical teams on endpoint needs.

Explore polymer carriers for corneal cell delivery

Cell sheets need carriers or injectable biomaterials; Pleryon designs ophthalmic polymer biomaterials and is in first-in-human for dry eye. A feasibility study could improve cell engraftment.

15%confidence

Evidence from the records

  • “Proprietary platforms for designing and controlling the structure of large synthetic and modified natural polymers, for drug delivery and injectable biomaterials.”
  • “Scalable corneal cell therapy: a new approach for a form of blindness with no satisfactory treatment.”
If it works
A material-transfer agreement and feasibility data.
First step
Send Pleryon a carrier specification and ask about MTA terms.

Investors1

A fund whose thesis fits

Apply to the EIC for clinic-entry funding

The EIC funds breakthrough biotech in Europe from seed with grants and equity, and the cash need to reach the clinic suits its risk appetite. EIC-backed network members (Lampsy Health, Leitspalt) can share learnings.

35%confidence

Evidence from the records

  • “Close the funding gap for breakthrough technologies in Europe by taking strategic risk and crowding in private capital.”
  • “High risk: long clinical and regulatory path, US$3M raised.”
If it works
Grant plus equity to fund GMP and the first trial.
First step
Book a pre-submission coaching session and draft the EIC short proposal.

Analyst reading of 21 Nov 2026, from the public record of the network. Method: analyst-ai.

Investors that fit

EIC Fund: the European Innovation Council's equity arm, investing €0.5M-30M in breakthrough European deep tech alongside EIC Accelerator grants.

Finnish corneal cell therapy with a granted patent, aiming at clinic ~2027: high-risk biotech the EIC is designed to de-risk.

45%confidence

Evidence from the records

  • “Ophthalmic cell therapy (cornea)”
  • “patent granted in Singapore (June 2026)”
Intro path
Business Finland (StemSight backer)
First step
Prepare an EIC Accelerator application for the first-in-human path.

Investor with no public profile in our data; its only known deal is an $8M pre-Series A extension in BioSapien.

Finnish ophthalmic cell therapy at seed — clinical-stage biotech, geography fit unknown.

20%confidence

Evidence from the records

  • “BioSapien”
  • “Ophthalmic cell therapy (cornea)”
  • “Corneal cell therapy at preclinical stage, clinical trials targeted around 2027”
Intro path
Founder-to-founder intro via BioSapien (network portfolio company of Globivest).
First step
Qualify Globivest via BioSapien first.

Chinese VC with no profile in our data; investor in Pleryon Therapeutics' Pre-A and Series A.

Finnish corneal cell therapy — ophthalmology, like Pleryon's dry-eye focus.

20%confidence

Evidence from the records

  • “Pleryon Therapeutics”
  • “Ophthalmic cell therapy (cornea)”
  • “Corneal cell therapy at preclinical stage, clinical trials targeted around 2027”
Intro path
Founder-to-founder intro via Pleryon Therapeutics (network portfolio company of Kaitai Capital).
First step
Qualify via Pleryon.

Chinese VC with no profile in our data; investor in Pleryon Therapeutics' Pre-A and Series A.

Finnish corneal cell therapy — ophthalmology overlap.

20%confidence

Evidence from the records

  • “Pleryon Therapeutics”
  • “Ophthalmic cell therapy (cornea)”
  • “Corneal cell therapy at preclinical stage, clinical trials targeted around 2027”
Intro path
Founder-to-founder intro via Pleryon Therapeutics (network portfolio company of Lapam Capital).
First step
Qualify via Pleryon.

Liverpool investor with no profile in our data; participated in Ocuwell's 2025 seed.

Finnish corneal therapy — eye-health adjacency to Ocuwell, non-UK.

15%confidence

Evidence from the records

  • “Ocuwell”
  • “Ophthalmic cell therapy (cornea)”
  • “Corneal cell therapy at preclinical stage, clinical trials targeted around 2027”
Intro path
Founder-to-founder intro via Ocuwell Limited (network portfolio company of LYVA Labs).
First step
Low priority.

Manchester/Leeds/Sheffield university-founded investor (£312M) backing spin-outs and IP-rich businesses in the North of England.

Finnish corneal therapy — IP-rich; non-UK.

15%confidence

Evidence from the records

  • “IP-rich businesses”
  • “Ophthalmic cell therapy (cornea)”
  • “Corneal cell therapy at preclinical stage, clinical trials targeted around 2027”
Intro path
Founder-to-founder intro via Ocuwell Limited (network portfolio company of Northern Gritstone).
First step
Low priority.

Bergen seed investor (Sarsia Seed II, ~€33M, state-private 50/50) investing NOK 5-20M in Norwegian life science, cleantech and renewables.

Finnish corneal cell therapy at preclinical stage: life-science fit, wrong geography.

15%confidence

Evidence from the records

  • “Ophthalmic cell therapy (cornea)”
  • “Finland”
First step
Low priority; geography mismatch.

Shenzhen life-science investor (since 2012) backing drug developers with phase 2/3 assets and device makers; backed Pleryon Therapeutics.

Corneal cell therapy, preclinical with trials targeted ~2027: too early versus phase 2/3 focus.

15%confidence

Evidence from the records

  • “Ophthalmic cell therapy (cornea)”
  • “R&D”
First step
Revisit at clinical stage.

Korean government drug-development fund supporting Korean biotech pipelines, including a 2026 grant to BILIX.

Finnish cell therapy — no Korean entity.

10%confidence

Evidence from the records

  • “"South Korea"”
  • “Ophthalmic cell therapy (cornea)”
  • “Corneal cell therapy at preclinical stage, clinical trials targeted around 2027”
Intro path
Founder-to-founder intro via BILIX (network portfolio company of Korea Drug Development Fund (KDDF)).
First step
Only with a Korean partner.

Investment analysis

3.3D

Grade D

Rank 123 of 151

Disruption7.0/10
Business model1.0/10
Market2.0/10
Risk(lower is better)8.0/10

Global score = mean of disruption, model, market and (11 − risk). Last updated 21 Nov 2026.

Promising science, but too early: revisit once it enters the clinic.

Disruption

7/10

Scalable corneal cell therapy: a new approach for a form of blindness with no satisfactory treatment.

Business model

1/10

Preclinical stage, trials targeted around 2027, no revenue.

Market

2/10

TAM $0.21bn → base 3; scalability 4/10 (−1); no international presence: preclinical stage → 2/10.

Risk

8/10

Lower is better

High risk: long clinical and regulatory path, US$3M raised.

Strengths

  • Recognized scientific expertise
  • Patent granted

Risks

  • Preclinical stage
  • High regulatory costs

Funding

$3M, disclosed
  1. ~2022-2023

    seed€500K (another figure of €1M is reported)

    Voima Ventures, Business Finland and others

  2. 2025-02

    seed extension€2.3M

    Voima Ventures, Business Finland, Stephen Industries, Biothom, Avohoidon Tutkimussäätiö

  3. 2020-2022

    prizenon-monetary

    BioFit 2020, TechTour 2022

Amount used in the study. €500K seed + €2.3M extension (Business Finland included); €1M seed variant as upper bound.

Note. ~€2.8M (€500K seed + €2.3M); a €1M round also reported

No 2026 funding round found; Singapore patent (June 2026) added to traction. Totals still vary by aggregator ($2.4M VCBacked, $2.8M Bouncewatch).

Team

  • Laura Koivusalo

    Co-founder & CEO

    Ocular regenerative medicine researcher from Tampere University; business development and strategy.

  • Tanja Ilmarinen

    Co-founder & CSO

    Ocular stem cell researcher (Tampere University).

  • Heli Skottman

    Co-founder & CTO

    Senior researcher in stem cells and ocular tissue engineering (Tampere University).

  • Aapo Kiviniemi

    Co-founder & Chief Legal Officer

    Lawyer, intellectual property strategy and negotiations.

Sources

Regional final
Finland (presumed)
Identification confidence
high
Founding year: 2021 (high confidence)
Tampere University spin-off founded in 2021 according to several consistent sources (ARM, press) alliancerm.org
  1. 1en.ain.ua/2025/02/13/stemsight-raises-eur23-m
  2. 2nordiclifescience.org/?p=91920
  3. 3nordicstartupnews.com/finlands-stemsight-first-human-stem-cell-startup-from-finla
  4. 4biospectrumasia.com/news/123/27824/singapore-grants-stemsight-patent-for-scalab
  5. 5vcbacked.co/company/stemsight

From the open study Startup World Cup 2026 by TIBOK, based on public sources, verified in November 2026. Scores are an analyst's judgment on an explicit grid, not the jury's.

Wall

Wall

No posts yet